TABLE 1.
Clinical characteristics of CSU patients.
| Clinical characteristics | CSU (n = 49) |
|---|---|
| Age, n (%) | |
| ≤45years | 36/49 (73.5) |
| >45years | 13/49 (26.5) |
| Sex, n (%) | |
| Male | 16/49 (32.7) |
| Female | 33/49 (67.4) |
| Disease activity level, n (%)† | |
| urticaria‐free | 0/46 (0) |
| well‐Controlled/minimal disease activity | 2/46 (4.4) |
| mild disease activity | 12/46 (26.1) |
| moderate disease activity | 17/46 (37) |
| severe disease activity | 15/46 (32.6) |
| Disease duration, n (%) | |
| <3m | 4/49 (8.2) |
| <6m | 11/49 (22.5) |
| <1year | 10/49 (20.4) |
| >1year | 24/49 (50) |
| Disease frequency, n (%) | |
| Every day | 39/49 (79.6) |
| 3x/week | 9/49 (18.4) |
| Every week | 0/49 (0) |
| Every month | 1/49 (2) |
| Diurnal variation, n (%) | |
| No variation | 10/49 (20.4) |
| More at day | 4/49 (8.2) |
| More at night | 35/49 (71.4) |
| Accompanying AE, n (%) | |
| No | 16/49 (32.7) |
| Yes | 33/49 (67.4) |
| Frequency† | |
| every day | 2/32 (6.3) |
| 3x/week | 4/32 (12.5) |
| 1x/week | 10/32 (31.3) |
| every month | 10/32 (31.3) |
| 2‐3x/y | 6/32 (18.8) |
| Location | |
| upper lip | 21/33 (63.6) |
| lower lip | 22/33 (66.7) |
| upper eyelid R | 15/33 (45.5) |
| upper eyelid L | 18/33 (54.6) |
| lower eyelid R | 15/33 (45.5) |
| lower eyelid L | 13/33 (39.4) |
| genital region | 3/33 (9.1) |
| Tongue | 5/33 (15.2) |
| CSU symptoms, n (%) | |
| Itch | 49/49 (100) |
| Burn | 38/49 (77.6) |
| Tight skin | 23/49 (46.9) |
| Pain | 17/49 (34.7) |
| Joint dysfunction | 12/49 (24.5) |
| History, n (%) | |
| Allergy in personal history | 31/49 (63.3) |
| Allergy in the family† | 27/48 (56.3) |
| H pylori gastritis | 2/49 (4.1) |
| CV profile, n (%) | |
| Obesity | 18/49 (36.7) |
| Arterial Hypertension | 14/49 (28.6) |
| Hypercholesterolemia | 13/49 (26.5) |
| Smoking | 9/49 (18.4) |
| SCORE2 and score2‐OP risk | |
| Grade 0 | 27/49 (55.1) |
| Grade 1 | 8/49 (16.3) |
| Grade 2 | 12/49 (24.5) |
| Grade 3 | 2/49 (4.1) |
| History of AID, n (%) | 11/49 (22.5) |
| Hashimoto's disease | 4/11 (36.4) |
| AI gastritis | 2/11 (18.2) |
| Alopecia areata | 2/11 (18.2) |
| Vitiligo | 2/11 (18.2) |
| Rheumatoid arthritis | 1/11 (9.1) |
| Diabetes type 1 | 1/11 (9.1) |
| Psoriasis | 1/11 (9.1) |
| Graves‐Basedow thyroiditis | 1/11 (9.1) |
| Psychiatric/psychologic history, n (%) | 13/49 (26.5) |
| Depression | 9/13 (69.2) |
| Anxiety | 3/13 (23.1) |
| Burn out | 2/13 (15.4) |
| ADHD | 1/13 (7.7) |
| Aggression | 1/13 (7.7) |
| Gastro‐intestinal complaints, n (%) | 29/49 (59.2) |
| Pyrosis | 18/29 (62.1) |
| Constipation | 8/29 (27.6) |
| Diarrhea | 7/29 (24.1) |
| Flatulence | 7/29 (24.1) |
| CSU triggers, n (%) | 40/49 (81.6) |
| Friction | 30/40 (75) |
| Heat | 22/40 (55) |
| Exercise | 13/40 (32.5) |
| Stress | 8/40 (20) |
| Physical agents | 7/40 (17.5) |
| Vibration | 5/40 (12.5) |
| Sun | 5/40 (12.5) |
| Cold | 3/40 (7.5) |
| Pressure | 2/40 (5) |
| Changes in temperature | 2/40 (5) |
| Other | 2/40 (5) |
| Stress, n (%) | |
| No | 6/49 (12.2) |
| Mild | 8/49 (16.3) |
| Moderate | 17/49 (34.7) |
| Severe | 18/49 (36.7) |
| Cause of stress† | |
| Family issues | 28/43 (65.1) |
| Work/school | 26/43 (60.5) |
| Disease | 26/43 (60.5) |
| Other | 2/43 (4.7) |
| Previous CSU treatment, n (%) | |
| No | 1/49 (2) |
| AH | 47/49 (95.9) |
| Oral CS | 11/49 (22.5) |
| Omalizumab | 0/49 (0) |
| Cyclosporin | 0/49 (0) |
| Dapsone | 0/49 (0) |
| Other | 2/49 (4.1) |
Note: Clinical data of patients with CSU are given as absolute numbers and percentages calculated from the data available (mostly n = 49, except for † where there was missing data in the patient's medical charts).
Abbreviations: ADHD, attention deficit hyperactivity disorder; AE, angioedema; AH, antihistamines; AI, auto‐immune; AID, auto‐immune diseases; CS, corticosteroids; CSU, chronic spontaneous urticaria; CV, cardiovascular.